HomeAIM • NYSEAMERICAN
add
AIM ImmunoTech Inc
Previous close
$0.43
Day range
$0.43 - $0.46
Year range
$0.32 - $0.75
Market cap
21.23M USD
Avg Volume
324.46K
P/E ratio
-
Dividend yield
-
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | 65.00K | 16.07% |
Operating expense | 14.06M | 150.48% |
Net income | -12.58M | -186.53% |
Net profit margin | -19.35K | -146.86% |
Earnings per share | -0.28 | -202.79% |
EBITDA | -13.95M | -158.93% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 13.07M | -61.77% |
Total assets | 19.38M | -52.13% |
Total liabilities | 9.15M | 352.82% |
Total equity | 10.23M | — |
Shares outstanding | 49.90M | — |
Price to book | 2.24 | — |
Return on assets | -148.22% | — |
Return on capital | -204.12% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | -12.58M | -186.53% |
Cash from operations | -9.76M | -60.78% |
Cash from investing | -214.00K | -106.36% |
Cash from financing | 147.00K | — |
Net change in cash | -9.82M | -263.08% |
Free cash flow | -6.09M | -111.15% |
About
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
Founded
1966
Headquarters
Website
Employees
27
